<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901784</url>
  </required_header>
  <id_info>
    <org_study_id>011972</org_study_id>
    <nct_id>NCT00901784</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Ortho-McNeil Pharmaceutical (Topamax®) 25 mg Topiramate Tablets Following a 50 mg Dose in Healthy Adult Males Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the single-dose relative bioavailability of&#xD;
      Ranbaxy and Ortho-McNeil Pharmaceutical (Topamax®) 25 mg topiramate tablets following a 50 mg&#xD;
      dose under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability&#xD;
      study performed on 24 healthy adult male volunteers and 4 alternates. All 28 subjects&#xD;
      completed the clinical phase of the study. In each period, subjects were housed from the&#xD;
      evening before dosing until after the 24-hour blood draw. Subjects were to return for the&#xD;
      48-, 72-, 96- and 120-hour blood draws. Both periods were separated by a washout period of 14&#xD;
      days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence evaluation of Topiramate 25mg tablets</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>25mg Tablets</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. This study involved healthy adult male volunteers, 18-45 years of age, weighing at&#xD;
             least 52 kg, who are within 15% of their ideal weights (Table of &quot;Desirable Weights of&#xD;
             Adults&quot;, Metropolitan Life Insurance Company, 1983).&#xD;
&#xD;
          2. Only medically healthy subjects with clinically normal laboratory profiles were&#xD;
             enrolled in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of significant:&#xD;
&#xD;
             • cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine,&#xD;
             immunologic, dermatologic, neurologic or psychiatric disease.&#xD;
&#xD;
             In addition, history or presence of:&#xD;
&#xD;
               -  Hypersensitivity or idiosyncratic reaction to topiramate&#xD;
&#xD;
               -  Nephrolithiasis or gout&#xD;
&#xD;
               -  Alcoholism or drug abuse within the past year&#xD;
&#xD;
          2. Subjects who had been on an abnormal diet (for whatever reason) during the 28 days&#xD;
             preceding the study.&#xD;
&#xD;
          3. Subjects who had any drugs or other substances known to be strong inhibitors of CYP&#xD;
             (cytochrome P450) enzymes within 10 days of study start.&#xD;
&#xD;
          4. Subjects who had used any drugs or other substances known to be strong inducers of CYP&#xD;
             (cytochrome P450) enzymes within 28 days of study start.&#xD;
&#xD;
          5. Subjects who, through completion of the study, would have donated in excess of:&#xD;
&#xD;
               -  500 mL of blood in 14 days, or&#xD;
&#xD;
               -  500-750 mL of blood in 14 days (unless approved by the Principal Investigator),&#xD;
&#xD;
               -  1000 mL of blood in 90 days,&#xD;
&#xD;
               -  1250 mL of blood in 120 days,&#xD;
&#xD;
               -  1500 mL of blood in 180 days,&#xD;
&#xD;
               -  2000 mL of blood in 270 days,&#xD;
&#xD;
               -  2500 mL of blood in 1 year,&#xD;
&#xD;
          6. Subjects who had participated in another clinical trial within 28 days of study start.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MDS Pharina Services (Clinical Research Center)</name>
      <address>
        <city>St. Laurent, Québec</city>
        <zip>H4R 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/default.htm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/default.htm</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2009</study_first_posted>
  <last_update_submitted>June 17, 2009</last_update_submitted>
  <last_update_submitted_qc>June 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Laboratories</organization>
  </responsible_party>
  <keyword>Topiramate fasting study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

